Pathogenic role of mitochondrial [correction of mitochondral] amyloid-beta peptide.

Abstract:

:Metabolic dysfunction is one of the early features in Alzheimer's disease (AD) affected brain. Amyloid-beta peptide (Abeta), a major peptide deposited in neuritic plaques, has been considered as an important initiating molecule in the pathogenesis of AD. However, the pathogenic role of Abeta remains to be determined. Here, we review current studies showing that progressive accumulation of Abeta occurs within the mitochondria of both transgenic mice overexpressing mutant Abeta peptide precursor protein and autopsied brains from AD patients. Interaction of Abeta with Abeta-binding alcohol dehydrogenase (ABAD), a short-chain alcohol dehydrogenase in the mitochondrial matrix, leads to mitochondrial dysfunction evidenced by increased reactive oxygen species generation, mitochondrial membrane permeability formation and caspase-3-like activity induction, and decreased activities of the Krebs cycle. These effects can be blocked by intracellular transduction of the ABAD decoy peptide. We hypothesize that Abeta-induced and mitochondria-dependent cytotoxic pathways might play an important role in AD pathogenesis and could be a potential therapeutic target.

journal_name

Expert Rev Neurother

authors

Chen JX,Yan SD

doi

10.1586/14737175.7.11.1517

subject

Has Abstract

pub_date

2007-11-01 00:00:00

pages

1517-25

issue

11

eissn

1473-7175

issn

1744-8360

journal_volume

7

pub_type

杂志文章,评审
  • The search for biomarkers in Parkinson's disease: a critical review.

    abstract::Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily presents with features of bradykinesia, rigidity and tremor, and has, as part of its core pathology, the degeneration of dopaminergic neurons in the substantia nigra pars compacta. There is a great need for the development of a reliabl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.12.1841

    authors: Antoniades CA,Barker RA

    更新日期:2008-12-01 00:00:00

  • Interventions to promote the evidence-based care of children with ADHD in primary-care settings.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a commonly occurring behavioral disorder among children. Community-based physicians are often the primary providers of services for children with ADHD. A set of consensus guidelines has been published by the American Academy of Pediatrics that provides best-practice d...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.5

    authors: Langberg JM,Brinkman WB,Lichtenstein PK,Epstein JN

    更新日期:2009-04-01 00:00:00

  • Update on the treatment of vitamin B6 dependent epilepsies.

    abstract::Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1648212

    authors: Mastrangelo M,Cesario S

    更新日期:2019-11-01 00:00:00

  • Barriers to the use of genetic information for the development of new epilepsy treatments.

    abstract::Genetic analysis is providing new information on the biological basis of epilepsy at a rapid pace; this article identifies factors acting as major barriers to use of these data for therapy development. Disease heterogeneity is a primary obstacle since so many genes can cause or predispose to epilepsy and the clinical ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 社论,评审

    doi:10.1586/14737175.2016.1115718

    authors: Ferraro TN

    更新日期:2016-01-01 00:00:00

  • Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.

    abstract::Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas. Notwithstanding a survival benefit in a subset of patients with high-grade gliomas, temozolomide (TMZ; Temodar®, Schering-Plough Pharmaceuticals, NJ, USA) is the primarily palliative treatment fo...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.32

    authors: Chamberlain MC

    更新日期:2010-10-01 00:00:00

  • Effect of second-generation antipsychotics on cognition: current issues and future challenges.

    abstract::Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.143

    authors: Hill SK,Bishop JR,Palumbo D,Sweeney JA

    更新日期:2010-01-01 00:00:00

  • Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.

    abstract::Background: Relatively little is known about the use of disease-modifying drugs (DMDs) for multiple sclerosis (MS) in the population-based universal healthcare setting. This study aimed to describe the characteristics of a population-based cohort with MS and their DMD exposure in four Canadian provinces. Methods: We i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1847085

    authors: Ng HS,Zhu F,Kingwell E,Zhao Y,Yao S,Ekuma O,Svenson LW,Evans C,Fisk JD,Marrie RA,Tremlett H

    更新日期:2021-01-01 00:00:00

  • The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder.

    abstract::Pharmacotherapy, psychotherapy and other nonpharmacological interventions are used in patients with major depressive disorder (MDD). However, 50% of the patients with MDD fail to achieve a response to first-line antidepressant treatment. In four of five acute monotherapy studies, once-daily extended-release quetiapine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.846520

    authors: Weisler R,McIntyre RS

    更新日期:2013-11-01 00:00:00

  • Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.

    abstract::Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, lea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1848548

    authors: Dorfman BJ,Jimenez-Shahed J

    更新日期:2021-01-01 00:00:00

  • Complementary and alternative medicine therapies in mood disorders.

    abstract::This article reviews the potential uses of complementary and alternative medicine (CAM) techniques for individuals with mood disorders. Mood disorders are among the most prevalent mental health issues today and there are many approaches towards their management. While many different types of medication are available, ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.77

    authors: Moss AS,Monti DA,Amsterdam JD,Newberg AB

    更新日期:2011-07-01 00:00:00

  • Triptanophobia in migraine: A case-control study on the causes and consequences of the nonuse of triptans in chronic migraine patients.

    abstract::Background: Triptanophobia is the excessive and inadequately justified concern about potential risks of triptans. We evaluated causes and consequences of nonuse of triptans in chronic migraine (CM) Methods: Case-control study. We included CM patients firstly referred to aheadache unit. Patients were cases or controls ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1842733

    authors: Martínez-Pías E,García-Azorín D,Minguez-Olaondo A,Trigo J,Sierra Á,Ruiz M,Guerrero ÁL

    更新日期:2021-01-01 00:00:00

  • Anti lingo 1 (opicinumab) a new monoclonal antibody tested in relapsing remitting multiple sclerosis.

    abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurode...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1378098

    authors: Ruggieri S,Tortorella C,Gasperini C

    更新日期:2017-11-01 00:00:00

  • Use of antiepileptic drugs in pregnancy.

    abstract::Babies born to mothers exposed to antiepileptic drugs (AEDs) are at increased risk for major congenital malformations, cognitive impairment and fetal death. For the millions of women with epilepsy, maintaining the safest drug that will successfully prevent seizures during pregnancy remains a primary consideration. The...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.7.1077

    authors: Tatum WO

    更新日期:2006-07-01 00:00:00

  • Tension-type headache.

    abstract::Tension-type headache (TTH) is the most prevalent of all headaches and also represents one of the most expensive clinical conditions for the health system. Despite the high impact of this disorder and the existence of well-established diagnostic criteria, knowledge about TTH is still quite limited. In most cases in wh...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.5.839

    authors: Speciali JG,Eckeli AL,Dach F

    更新日期:2008-05-01 00:00:00

  • Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

    abstract::Evaluation of: Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a Phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 7, 796-804 (2008). ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.9.3.319

    authors: Longbrake EE,Racke MK

    更新日期:2009-03-01 00:00:00

  • Rivastigmine for Alzheimer's disease.

    abstract::Alzheimer's disease is the most common form of neurodegenerative dementia and poses considerable health challenges to both patients and their families. Rivastigmine is a powerful slow-reversible, noncompetitive carbamate cholinesterase inhibitor that is approved for the treatment of mild-to-moderate Alzheimer's diseas...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.5.563

    authors: Desai AK,Grossberg GT

    更新日期:2005-09-01 00:00:00

  • Advances in understanding spontaneous intracerebral hemorrhage: insights from neuroimaging.

    abstract::Spontaneous (non-traumatic) symptomatic intracerebral hemorrhage is a devastating form of stroke, with very high overall mortality and morbidity. Even with the best current medical or surgical treatment, outcomes still remain poor. By contrast with ischemic stroke, the incidence of intracerebral hemorrhage is not decr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.918506

    authors: Wilson D,Charidimou A,Werring DJ

    更新日期:2014-06-01 00:00:00

  • Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.

    abstract::Parkinson's disease (PD) is characterized clinically by rest tremor, rigidity, bradykinesia and pathologically by degeneration of nigrostriatal dopamine neurons. Motor fluctuations (wearing off) and motor complications (dyskinesia) are common features of the long-term treatment of PD. Ongoing clinical and preclinical ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.868306

    authors: Ramirez-Zamora A,Molho E

    更新日期:2014-01-01 00:00:00

  • Acute ischemic stroke management: concepts and controversies.A narrative review.

    abstract:INTRODUCTION:Amongst the 25.7 million survivors and 6.5 million deaths from stroke between 1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases, respectively. With patients still suffering from complications and stroke recurrence, more questions have been raised as to how we can better i...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1836963

    authors: Li KHC,Jesuthasan A,Kui C,Davies R,Tse G,Lip GYH

    更新日期:2021-01-01 00:00:00

  • Internet-supported versus face-to-face cognitive behavior therapy for depression.

    abstract::Major depression and depressive symptoms are highly prevalent and there is a need for different forms of psychological treatments that can be delivered from a distance at a low cost. In the present review the authors contrast face-to-face and Internet-delivered cognitive behavior therapy (ICBT) for depression. A total...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.2015.1125783

    authors: Andersson G,Topooco N,Havik O,Nordgreen T

    更新日期:2016-01-01 00:00:00

  • Recent genetic advances in ADHD and diagnostic and therapeutic prospects.

    abstract::Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.4.453

    authors: Hawi Z,Kirley A,Lowe N,Fitzgerald M,Gill M

    更新日期:2003-07-01 00:00:00

  • Evidence-based treatment of Tourette's disorder and chronic tic disorders.

    abstract::Introduction: Chronic Tic Disorders and Tourette's Disorder (collectively referred to as TD) are characterized by sudden, rapid, and repetitive motor movements or vocalizations called tics. Children, adolescents, and adults with TD often experience co-occurring psychiatric symptoms and impairments in multiple domains....

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1643236

    authors: Essoe JK,Grados MA,Singer HS,Myers NS,McGuire JF

    更新日期:2019-11-01 00:00:00

  • Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?

    abstract::Braak's proposal that, in patients with Parkinson's disease, Lewy bodies and neurites progressively invade the brain through regions connected to autonomic and olfactory centers remains contentious. Confounding factors include the lack of an in vivo marker to examine the progression of Lewy pathology, the retrospectiv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.47

    authors: Halliday G,McCann H,Shepherd C

    更新日期:2012-06-01 00:00:00

  • Post-traumatic headache.

    abstract::Post-traumatic headache (PTH) is a very controversial disorder, particularly when it comes to chronic PTH following mild closed head injury and headache attributed to whiplash injury. Nevertheless, mild traumatic brain injury is very common in Western societies, affecting approximately 1.8 million individuals in the U...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.84

    authors: Obermann M,Holle D,Katsarava Z

    更新日期:2009-09-01 00:00:00

  • Use of neural stem cells as therapeutic vehicles for the treatment of malignant glioma.

    abstract::The prognosis for patients with malignant glioma, the most common primary intracranial neoplasm, remains dismal despite significant progress in neuro-oncological therapies and technology. This stems from the inability of current treatment strategies to address the highly invasive nature of this disease. Malignant glia...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.6.883

    authors: Ehtesham M,Kabos P,Black KL,Yu JS

    更新日期:2003-11-01 00:00:00

  • Evaluating and managing severe headache in the emergency department.

    abstract::Introduction: Headache is the fifth most common reason to visit an emergency department (ED). In most of the cases, headache is benign and has a primary origin, with migraine as the most common diagnosis. Inappropriate use of ED for non-emergency conditions causes overcrowding, unnecessary testing, and increased medic...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2021.1863148

    authors: Luciani M,Negro A,Spuntarelli V,Bentivegna E,Martelletti P

    更新日期:2021-01-04 00:00:00

  • Voxel-based morphometry in Alzheimer's disease.

    abstract::Recent morphometric MRI studies have investigated brain volume abnormalities associated with the diagnosis of Alzheimer's disease (AD) using voxel-based morphometry (VBM). This technique allows the assessment of gray matter volumes in subjects with AD or related conditions compared with healthy controls in an automate...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.11.1691

    authors: Busatto GF,Diniz BS,Zanetti MV

    更新日期:2008-11-01 00:00:00

  • New therapeutics in spine metastases.

    abstract::The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.831

    authors: Bilsky MH

    更新日期:2005-11-01 00:00:00

  • Update on emerging therapies for multiple sclerosis.

    abstract::The American Academy of Neurology is an international professional organization of more than 22,000 neurologists and neuroscience professionals. This year the annual meeting was held in Toronto, ON, Canada. A large number of scientific sessions presented numerous advances in the diagnosis, molecular pathogenesis and t...

    journal_title:Expert review of neurotherapeutics

    pub_type:

    doi:10.1586/ern.10.98

    authors: Yiu EM,Banwell B

    更新日期:2010-08-01 00:00:00

  • Microbiota-gut brain axis involvement in neuropsychiatric disorders.

    abstract::Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1638763

    authors: Iannone LF,Preda A,Blottière HM,Clarke G,Albani D,Belcastro V,Carotenuto M,Cattaneo A,Citraro R,Ferraris C,Ronchi F,Luongo G,Santocchi E,Guiducci L,Baldelli P,Iannetti P,Pedersen S,Petretto A,Provasi S,Selmer K,Sp

    更新日期:2019-10-01 00:00:00